ENPP1-IN-19 is an orally active ENPP1 inhibitor that enhances anti-PD-L1 response and suppresses tumor growth in the CT26 syngeneic model; it also potentiates STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence.